A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480 [ispronicline]/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

Trial Profile

A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480 [ispronicline]/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Aripiprazole; Ispronicline
  • Indications Alzheimer's disease; Bipolar disorders; Depressive disorders; Schizophrenia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Jun 2009 Status changed from suspended to completed, according to ClinicalTrials.gov.
    • 15 Jan 2009 Status changed from recruiting to suspended due to the observation of a serious adverse event in another ispronicline trial according to ClinicalTrials.gov; this trial has been temporarily suspended during further evaluation.
    • 24 Sep 2008 Planned end date changed from 1 Aug 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top